PharmedOut, a new project that educates physicians on how
pharmaceutical companies influence prescribing, is previewing a timely video
about Zyprexa (olanzapine), an antipsychotic drug approved by the FDA to treat
schizophrenia and bipolar disorder. In this video Shahram Ahari, a former
pharmaceutical company representative, tells how he sold the drug. Nearly
a decade after its introduction, a drug once hailed as a breakthrough treatment
is being assailed for its negative side effects. Antipsychotic drugs are not
risk-free, but doctors and patients have long complained that Zyprexa causes
obesity and diabetes. This week, the New York Times reported that studies
on the frequency of weight gain were underreported by the manufacturer. PharmedOut
is an independent physician-run project funded through the Attorney General
Consumer and Prescriber Education grant program.
** PharmedOut.org will launch on Tuesday, January 9, 2007
Contact: 202-687-1191
| TITLE: LOCATION: DATE: RUNTIME: SYNOPSIS: |
Zyprexa Drug Rep Washington, D.C. December 18, 2006 5:25 PharmedOut, a new project that educates physicians on how pharmaceutical companies influence prescribing, is previewing a timely video about Zyprexa (olanzapine), an antipsychotic drug approved by the FDA to treat schizophrenia and bipolar disorder. |